{"id":"NCT04488419","sponsor":"Athira Pharma","briefTitle":"ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease","officialTitle":"A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Mild to Moderate Alzheimer's Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2020-09-28","primaryCompletion":"2024-07-15","completion":"2024-07-15","firstPosted":"2020-07-28","resultsPosted":"2025-04-04","lastUpdate":"2025-04-04"},"enrollment":554,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Alzheimer Disease","Dementia of Alzheimer Type"],"interventions":[{"type":"DRUG","name":"ATH-1017","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Dosage","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease with a randomized treatment duration of 26-weeks.","primaryOutcome":{"measure":"Global Statistical Test (GST) Score","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Placebo","deltaMin":-0.126,"sd":0.0683},{"arm":"ATH-1017 40 Milligrams (mg)","deltaMin":-0.208,"sd":0.0707}],"pValues":[]},"eligibility":{"minAge":"55 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":16},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["21514250","38599894"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":218},"commonTop":["Injection site reactions","COVID-19","Fall","Eosinophilia","Pruritus"]}}